Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Absolute Count of Circulating, Classical, CD14 ++ /CD16 - Monocytes Is a Poor Prognosis Marker in Chronic Myelomonocytic Leukemia (CMML)

Matthieu Jestin, Sihem Tarfi, PharmD, Bouchra Badaoui, PharmD, Nicolas Freynet, PharmD, Ivan Sloma, PharmD,PhD, Margot Morabito, Sébastien Maury, MD PhD, Pierre Fenaux, MD PhD, Eric Solary, MD PhD, Dorothée Selimoglu-Buet, PhD, Orianne Wagner Ballon, MD PhD

Blood (2019) 134 (Supplement_1): 4242.

https://doi.org/10.1182/blood-2019-121794

Published: 2019

Journal Articles

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Ivan Sloma, PharmD, PhD, Philip Beer, PhD FRCPath, MRCP, Christophe Desterke, PhD, Elizabeth Bulaeva, Misha Bilenky, Michelle Moksa, Kamini Raghuram, Cedric Brimacombe, Karen Lambie, Ali G Turhan, MD PhD, Orianne Wagner-Ballon, MD PhD, Philippe Gaulard, MD PhD, R. Keith Humphries, MD PhD, Martin Hirst, PhD BS, Connie J. Eaves, PhD

Blood (2019) 134 (Supplement_1): 4139.

https://doi.org/10.1182/blood-2019-127839

Published: 2019

Journal Articles

Aryl Hydrocarbon Receptor (AhR) Pathway Directly Controls Hematopoietic Proliferation in Chronic Myeloid Leukemia (CML) and Its Inhibition Allows Massive Expansion of Leukemic Progenitors and Stem Cells

Melanie Gentil, MD, Patricia Hugues, Gladys Telliam, Ivan Sloma, PharmD,PhD, Seda Baykal, Jerome Artus, PhD, Agnes Guerci, MD, Hyacinthe Johnson Ansa, Adlen Foudi, PhD, Annelise Bennaceur-Griscelli, MD PhD, Ali G Turhan, MD PhD

Blood (2015) 126 (23): 4013.

https://doi.org/10.1182/blood.V126.23.4013.4013

Published: 2015

Journal Articles

A Bio-Integrative Approach Identifies an Inflammatory Signature in Chronic Myeloid Leukemia (CML) Stem Cells That Is Highly Perturbed in CML Blast Crisis and Involves REL transcription Factor

Christophe Desterke, PhD, Ludovic Marie-Sainte, Amine Sbitti, PhD, Ali Naama, Annelise Bennaceur-Griscelli, MD PhD, Ali G Turhan, MD PhD, Ivan Sloma, PharmD,PhD

Blood (2015) 126 (23): 4017.

https://doi.org/10.1182/blood.V126.23.4017.4017

Published: 2015

Journal Articles

Whole Genome Sequencing Of Chronic Myeloid Leukemia (CML)-Derived Induced Pluripotent Stem Cells (iPSC) Reveals Faithful Genocopying Of Highly Mutated Primary Leukemic Cells

Ivan Sloma, PharmD, PhD, Maria Teresa Mitjavila-Garcia, PhD, Olivier Feraud, Noufissa Oudrhiri, Lucie Tosca, PharmD, PhD, Sanaa El Marsafy, MD, PhD, Emilie Gobbo, Dominique Divers, Alexis Proust, Frank Griscelli, PharmD PhD, Gerard Tachdjian, MD, PhD, Marco A. Marra, PhD, Connie J Eaves, PhD, Annelise Bennaceur-Griscelli, MD, PhD, Ali G Turhan, MD, PhD

Blood (2013) 122 (21): 514.

https://doi.org/10.1182/blood.V122.21.514.514

Published: 2013

Journal Articles

Evaluation of Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia (CML) Patients in Complete Molecular Remission Induced by First Line TKI Therapies

Jean-Claude Chomel, PharmD, PhD, Marie Laure Bonnet, Nathalie Sorel, PhD, Ivan Sloma, PharmD, PhD, Alexis Proust, Annelise Bennaceur-Griscelli, MD, PhD, Delphine Rea, MD, PhD, Madalina Uzunov, M.D., Laurence Legros, MD, PhD, Shanti Ame, MD, Anne Marfaing-Koka, Agnès Guerci, MD, Philippe Rousselot, MD, PhD, Ali G Turhan, M.D., PhD

Blood (2012) 120 (21): 3726.

https://doi.org/10.1182/blood.V120.21.3726.3726

Published: 2012

Journal Articles

A Single Chronic Myeloid Leukemia (CML) Stem Cell Harboring Both BCR-ABL and JAK2-V617F Mutation Modeled by Induced Pluripotency

Ivan Sloma, PharmD, PhD, Maria Teresa Mitjavila-Garcia, PhD, Olivier Feraud, Lucie Tosca, PharmD, PhD, Sanaa El Marsafy, MD, PhD, Emilie Gobbo, Dominique Divers, Alexis Proust, Marie Laure Bonnet, Frank Griscelli, PharmD PhD, Gerard Tachdjian, MD, PhD, Annelise Bennaceur-Griscelli, MD, PhD, Ali G Turhan, M.D., PhD

Blood (2012) 120 (21): 3728.

https://doi.org/10.1182/blood.V120.21.3728.3728

Published: 2012

Journal Articles

Longterm Serial Transplantability of BCR-ABL+ Chronic Phase CML Cells Is Predicted by a 6-Week LTC-IC Assay.

Ivan Sloma, PharmD, PhD, Philip A Beer, BM, MRCP, MRCPath, Kyi Min Saw, Matthiew Chan, Karen Lambie, Bobby Johnston, Xiaoyan Jiang, MD, PhD, Connie J. Eaves, PhD

Blood (2012) 120 (21): 2770.

https://doi.org/10.1182/blood.V120.21.2770.2770

Published: 2012

NARROW

The Absolute Count of Circulating, Classical, CD14 ++ /CD16 - Monocytes Is a Poor Prognosis Marker in Chronic Myelomonocytic Leukemia (CMML)

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Aryl Hydrocarbon Receptor (AhR) Pathway Directly Controls Hematopoietic Proliferation in Chronic Myeloid Leukemia (CML) and Its Inhibition Allows Massive Expansion of Leukemic Progenitors and Stem Cells

A Bio-Integrative Approach Identifies an Inflammatory Signature in Chronic Myeloid Leukemia (CML) Stem Cells That Is Highly Perturbed in CML Blast Crisis and Involves REL transcription Factor

Whole Genome Sequencing Of Chronic Myeloid Leukemia (CML)-Derived Induced Pluripotent Stem Cells (iPSC) Reveals Faithful Genocopying Of Highly Mutated Primary Leukemic Cells

Evaluation of Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia (CML) Patients in Complete Molecular Remission Induced by First Line TKI Therapies

A Single Chronic Myeloid Leukemia (CML) Stem Cell Harboring Both BCR-ABL and JAK2-V617F Mutation Modeled by Induced Pluripotency

Longterm Serial Transplantability of BCR-ABL+ Chronic Phase CML Cells Is Predicted by a 6-Week LTC-IC Assay.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only